scholarly journals Nomogram for predicting cancer specific survival in inflammatory breast carcinoma: a SEER population-based study

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7659 ◽  
Author(s):  
Haige Zhang ◽  
Guifen Ma ◽  
Shisuo Du ◽  
Jing Sun ◽  
Qian Zhang ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Radical Mastectomy ◽  
Stage Iii ◽  
Predictive Tool ◽  
Cancer Specific Survival ◽  
Trimodality Therapy ◽  
Inflammatory Breast Carcinoma

The clinicopathological features of inflammatory breast carcinoma (IBC), the effect of therapeutic options on survival outcome and the identification of prognostic factors were investigated in this study. Information on IBC patients were extracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Cox proportional hazard regression was used to determine potential significant prognostic factors of IBC. A nomogram was then constructed to evaluate patient survival based on certain variables. Univariate and multivariate analyses revealed that race (p < 0.001), M stage (p < 0.001), surgery (p = 0.010), chemotherapy (CT) (p < 0.001), tumor size (p = 0.010), estrogen receptor (p < 0.001), progesterone receptor (p = 0.04), and human epidermal growth factor receptor 2 (p < 0.001) were all independent risk factors. The concordance index (C-index) of the nomogram was 0.735, which showed good predictive efficiency. Survival analysis indicated that IBC patients without CT had poorer survival than those with CT (p < 0.001). Stratified analyses showed that modified radical mastectomy (MRM) had significant survival advantages over non-MRM in patients with stage IV IBC (p = 0.031). Patients treated with or without CT stratified by stage III and stage IV showed better survival than those without stage III and IV (p < 0.001). Trimodality therapy resulted in better survival than surgery combined with CT or CT alone (p < 0.001). Competing risk analysis also showed the same results. The nomogram was effectively applied to predict the 1, 3 and 5-year survival of IBC. Our nomogram showed relatively good accuracy with a C-index of 0.735 and is a visualized individually predictive tool for prognosis. Treatment strategy greatly affected the survival of patients. Trimodality therapy was the preferable therapeutic strategy for IBC. Further prospective studies are needed to validate these findings.

A CROSS SECTIONAL STUDY OF BREAST CANCER HISTOMORPHOLOGY AND ITS CORRELATION WITH ER/PR, HER 2NEU AND KI-67 EXPRESSION IN A TERTIARY CARE HOSPITAL AT KANPUR

2021 ◽  
pp. 9-12
Author(s):  
Mahendra Singh ◽  
Shobha Dwivedi ◽  
Yukteshwar Mishra ◽  
Sakshi Tripathi
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Tertiary Care ◽  
Radical Mastectomy ◽  
Cross Sectional Study ◽  
Low Grade ◽  
Care Hospital ◽  
Sectional Study ◽  
Ki 67 ◽  
Cross Sectional

BACKGROUND Breast carcinoma is the most well-known malignancy in women. Different predictive and prognostic factors, for example, estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (Her2neu), and Ki67 could inuence breast carcinoma behaviour, yet to date no authoritative connection has been set up among them and breast carcinoma subtypes. In this way present study was done to determine the interrelationships of these predictive and prognostic factors for breast carcinoma. METHODS In this cross sectional study, a total of 50 lumpectomy, modied radical mastectomy specimens of diagnosed carcinoma breast were included in this study. The histopathological grading of the breast carcinoma was performed by Nottingham modication of the Bloom Richardson grading system. All the cases went through immunohistochemistry for ER, PR, Her2neu and Ki67 expression. Association of ER, PR, Her2neu and Ki67 with different histomorphology was established. RESULTS The ER positivity was signicantly lower in tumors >5 cm size whereas Ki67was signicantly increased with increased tumor size. The ER positivity was signicantly lower in high grade tumors as compared to low grade tumors. The positive ER, PR, Her2neu and Ki67 were comparable in between premenopausal and post-menopausal age groups CONCLUSION The present study concludes that ER, PR show inverse while ki67 showed a direct relationship with the tumor grade. Correlation of histomorphology of breast tumor and Her2neu status could not be established.

scholarly journals Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease

Cancer ◽  
2004 ◽  
Vol 100 (5) ◽  
pp. 920-928 ◽  
Author(s):  
Stanley L. Liauw ◽  
Rashmi K. Benda ◽  
Christopher G. Morris ◽  
Nancy Price Mendenhall
Keyword(s):  
Breast Carcinoma ◽  
Trimodality Therapy ◽  
Inflammatory Breast Carcinoma

Mediastinal Mass with Bone Marrow Involvement Is a Favorable Factor for Childhood T-Lymphoid Malignancy in Japan.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4525-4525
Author(s):  
Megumi Oda ◽  
Keiko Yumura-Yagi ◽  
Junichi Hara ◽  
Shinichiro Nishimura ◽  
Akio Tawa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bone Marrow ◽  
Prognostic Factors ◽  
T Cell ◽  
Mediastinal Mass ◽  
Bone Marrow Involvement ◽  
Stage Iv ◽  
Stage Iii ◽  
Lymphoid Malignancy ◽  
Specific Protocol

Abstract T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) account for most of the childhood T-lymphoid malignancy(LM). T-ALL is usually treated by the same protocol to the B-progenitor ALL. It is obvious that biologically, T-cell behaviors are different from those of B-progenitor cell, and cell origins are same among T-ALL and T-LBL. Thus we conducted a strategy initiating T-ALL specific protocol, differing from protocols for B-progenitor ALL. Furthermore, we indicated the same protocol to advanced T-LBL. The aims of this study were to evaluate the efficacy and safety of indicating the same protocol for childhood T-ALL and advanced T-LBL, and to reveal the prognostic factors of childhood T-LM. 70 eligibleT-ALL patients enrolled in the JACLS ALL-97 study between 1997-2001, and 32 eligible patients with stage III and IV T-LBL enrolled in the JACLS NHL-T98 trial between 1998-2002 were analyzed. Median age was 9y8m (2y~15y3m) for T-ALL and 11y11m (3y~15y4m) for T-LBL. Male/female ratio was 46/24, 26/6, respectively. Mediastinal mass was found in 31/70(44.3%) for T-ALL, 19/21(90.5%) for stageIII and 6/11(54.5%) for stageIV T-LBL. The treatment for 2 years consisted of the induction therapy (VCR, HD-MTX, CA, PSL, ASP), the 5-drug consolidation therapy A and B, both including high dose of ASP, and maintenance therapy with block-rotated treatment using drugs above. Complete remission(CR) at the end of induction therapy was obtained 65/70(92.9%) for T-ALL, 15/21(71.4%) for stage III and 10/11(90.9%) for stage IV T-NHL. 5-year overall survival(OAS) rate for T-ALL, stage III and stage IV T-LBL was 81.1%, 63.9% and 81.8%, respectively. 5-year event free survival (EFS) rate was 72.9%, 47.6% and 72.3%, respectively. Relapse after CR occurred in 12/65 with T-ALL, 6/15 with stage III and 1/10 with stage IV T-LBL. Single variant analysis revealed that there were no significant difference in OAS or EFS for T-ALL patients based on WBC, NCI index, but statistical difference in OAS or EFS based on age(older than 10y worse), the existence of mediastinal mass(absence, worse) In T-LBL, there were no statistical differences based on age, existence of mediastinal mass. Multivariate analysis revealed, for T-ALL and T-LBL patients as a whole, that age > 10 years was a risk factor in both OAS and EFS, absence of mediastinal mass and stage III T-LBL were risk factors in OAS. Our data shows that indicating same T-cell specific protocol, for T-ALL and advanced T-LBL has a potential to improve the prognosis of T-LM. The older age, and stage III T-LBL appeared as prognostic factors. Moreover, mediastinal mass with bone marrow involvement was a favorable factor for childhood T-LM. Although some risk factors were documented, it is needed to clarify unknown prognostic factors and develop the more effective, stratified T-cell specific protocols.

scholarly journals Treatment and Outcomes of Colorectal Cancer in Armenia: A Real-World Experience From a Developing Country

2020 ◽  
pp. 1286-1297
Author(s):  
Samvel Bardakhchyan ◽  
Sergo Mkhitaryan ◽  
Davit Zohrabyan ◽  
Liana Safaryan ◽  
Armen Avagyan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Prognostic Factors ◽  
Cox Regression ◽  
Survival Rates ◽  
Stage Iv ◽  
Final Analysis ◽  
Stage Ii ◽  
Stage Iii ◽  
Rank Test

PURPOSE In Armenia, colorectal cancer (CRC) is one of the most frequently diagnosed cancers. It is in the third place by incidence. The aim of this study was to evaluate treatment and outcomes of CRC in Armenia during the last 9 years. MATERIALS AND METHODS For this retrospective hospital-based study, we have collected data from two main oncology centers in Armenia: National Oncology Center and “Muratsan” Hospital of Yerevan State Medical University. The information about patients with CRC who were treated at these two centers between January 1, 2010 and July 1, 2018 was collected from the medical records. Log-rank test and Kaplan-Meier curves were used for survival analysis. Prognostic factors were identified by Cox regression. RESULTS A total of 602 patients with CRC were involved in the final analysis. Median follow-up time was 37 months (range, 3-207 months). A total of 8.6% of patients had stage I, 32.9% stage II, 38.0% stage III, and 17.6% stage IV cancer; for 2.7% patients, the stage was unknown. The main independent prognostic factors for overall survival (OS) were tumor stage, grade, and histology. Adjuvant chemotherapy has been shown to improve survival in stage II colon cancer and stage III rectal but not in stage II rectal cancer. Radiotherapy did not yield survival improvement in stage II or III rectal cancer. Three- and 5-year OS rates were 62.9% and 51.8% for all stages combined and 79.7% and 68.5% for stages I-II, 62.5% and 48.4% for stage III, and 24.4% and 17% for stage IV respectively. CONCLUSION As seen from our results, our survival rates are lower than those of the developed world. Additional research is needed to identify the underlying reasons and to improve patients’ treatment and outcomes in Armenia.

scholarly journals Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer

2020 ◽  
Author(s):  
H. Adderley ◽  
F. H. Blackhall ◽  
C. R. Lindsay
Keyword(s):  
Small Molecule ◽  
Kinase Inhibitors ◽  
Checkpoint Inhibitors ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Stage Iii ◽  
Driver Mutations ◽  
Anaplastic Lymphoma ◽  
Significant Toxicity ◽  
Stage Iv Disease

Abstract Treatment stratification in stage IV NSCLC is guided by identification of oncogene driver mutations. Actionable mutations with current licenced therapeutic agents include epidermal growth factor receptor (EGFR), rearrangements of anaplastic lymphoma kinase (ALK), ROS-1 and BRAF V600. Alongside progress with small molecule therapy, developments in immune checkpoint inhibitors (CPIs) have transformed the landscape of stage III and stage IV NSCLC. The success of CPIs has led to evaluation with small molecule therapy in both concurrent and sequential settings. In this review we summarise recent results of combination CPIs and tyrosine kinase inhibitors (TKIs) in stage IV NSCLC, detailing significant toxicity and its potential mechanisms with both concurrent and sequential approaches. As more therapeutic targets are being discovered it is becoming increasingly important for clinicians to correctly sequence therapy for delivery of safe and effective treatment. In addition to stage IV disease we suggest that comprehensive molecular profiling of key NSCLC drivers, particularly in stage III disease, will help to inform optimal treatment sequencing and minimise potential toxicity.

scholarly journals The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xingtong Zhou ◽  
Zhibo Zheng ◽  
Yan Li ◽  
Weiwei Zhao ◽  
Yan Lin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Clinical Features ◽  
Ductal Carcinoma ◽  
Cox Proportional Hazards ◽  
Rank Test ◽  
Cancer Specific Survival ◽  
Infiltrating Ductal Carcinoma ◽  
Mucinous Breast Carcinoma

Abstract Background At present, the characteristics of mucinous breast carcinoma (MBC) and the factors affecting its prognosis are controversial. We compared the clinical features of MBC with those of infiltrating ductal carcinoma (IDC) and summarized the relevant prognostic factors. Methods The Surveillance, Epidemiology, and End Results (SEER) database includes information on 10,593 patients diagnosed with MBC between 2004 and 2016. Chi-square tests and analyses were used to analyze differences in variables between the MBC and IDC groups. Univariate and multivariate Cox proportional hazards models were used to assess the relative impacts of risk factors on cancer-specific survival (CSS) in patients. Kaplan-Meier survival curves were constructed to assess cancer-specific mortality and were compared using the log-rank test. Results From 2004 to 2016, 10,593 people were diagnosed with MBC, and 402,797 were diagnosed with IDC. Patients with MBC had significantly higher 5−/10-year CSS rates (96.4%/93.4%) than those with IDC (89%/83.8%). Compared with IDC patients, MBC patients had less lymph node metastasis, an earlier stage, a higher rate of hormone receptor positivity and a lower expression rate of HER2. Univariate and multivariate analyses showed that age ≥ 60 years old (HR = 1.574, 95%CI: 1.238–2.001, P < 0.001), singled status (HR = 1.676, 95%CI: 1.330–2.112, P < 0.001) and advanced TNM/SEER stage were independent prognostic risk factors for MBC. In addition, positive estrogen receptor (HR = 0.577, 95%CI: 0.334–0.997, P = 0.049), positive progesterone receptor (HR = 0.740, 95%CI: 0.552–0.992, P = 0.044), surgical treatment (HR = 0.395, 95%CI: 0.288–0.542, P < 0.001) and radiotherapy (HR = 0.589, 95%CI: 0.459–0.756, P < 0.001) were identified as protective factors. Conclusion Compared with IDC, MBC has a better prognosis. For patients with MBC, we identified prognostic factors that can help clinicians better assess patient outcomes and guide individualized treatment.

scholarly journals Tumor-Infiltrating Lymphocytes in Breast Carcinoma: Immunohistochemical Analysis

2018 ◽  
Vol 3 (12) ◽  
Author(s):  
Dr. Amol R. R. Rajhans, MD ◽  
Dr. Deepak S. Howale
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
T Lymphocytes ◽  
Clinical Stage ◽  
Stage Iv ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Cd4 Cells ◽  
Infiltrating Lymphocytes

Breast cancer is the most common invasive cancer in women, and the second main cause of cancer death in women, after lung cancer. Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. In 2017, around 252, 710 new diagnoses of breast cancer are expected in women, and around 40,610 women are likely to die from the disease. Awareness of the symptoms and the need for screening are important ways of reducing the risk. Material and Methods: This retrospective study was carried out in the department of Pathology, DCP Consultant Pathologist Shashwat Hospitals, Pune, a total of 38 retrospective breast carcinoma tissues were obtained from female patients. Representative paraffin blocks and haematoxylin and eosin (HandE)-stained sections were retrieved from the pathology department. The patients' records were reviewed to look for the patient age and the clinical stage of the disease. The stage of the cancer was reported according to the American Joint Committee of Cancer. As tissue and patient data was collected in an anonymous way no written or informed consent was required for the study purpose. Results and Observations: According to data by clinical staging Stage I, Stage II, Stage III and Stage IV were 16 (42.11%), 11(28.95%), 7 (18.42%) and 4 (10.53%) respectively. According to histology Stage I, Stage II, Stage III and Stage IV were 2 (5.26%), 11(28.95%), 24 (63.16%) and 1 (2.63%) respectively. Hand E-stained sections showed that tumour-infiltrating lymphocytes (TILs) were present in 31 of the 38 carcinomas (81.58%). Majority of theTILs were T lymphocytes and was present in all 31 cases. CD4+ cells were seen31 patients and CD 8+ were seen in 25 cases. B cells were seen in 21 cases. TILs were analysed according to the clinical stage of breast cancer, stages III and IV tumors showed significantly higher densities of total lymphocytes, T lymphocytes, and CD4+ lymphocytes as compared to stage II tumors. Lymphocyte immuno phenotypes and the total TILs also showed a high significantly positive correlation between each lymphocyte population/subpopulation and the total TILs. Conclusion: T and B lymphocytes were expressed in breast carcinoma with High prevalence of T lymphocytes CD4+ cells. However larger no of cases are required to confirm the findings and extensive large studies are required.

scholarly journals Cancer-specific survival by stage of bladder and urinary tract cancers and factors collected by Mallorca Cancer Registry associated to survival.

2020 ◽  
Author(s):  
Maria Ramos ◽  
Joana Ripoll ◽  
Juan José Montaño ◽  
Jaume Pons ◽  
Alberto Ameijide ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Cancer Registry ◽  
Cox Model ◽  
Stage Iv ◽  
Stage I ◽  
Stage Ii ◽  
Stage Iii ◽  
Cancer Specific Survival ◽  
Non Invasive

Abstract Background: Information about survival by stage in bladder cancer is scarce. Objectives: 1) to find out the distribution of bladder and urinary tract cancers by stage; 2) to determine cancer-specific survival by stage of bladder and urinary tract cancers; 3) to identify factors that explain and predict the likelihood of survival and the risk of dying from these cancers.Methods: Incident bladder and urinary tract cancer cases diagnosed between 2006 and 2011 were identified through the Mallorca Cancer Registry. Inclusion criteria: cases with codes C65–C68 (ICD-O 3) with any behaviour. DCO cases were excluded. We collected: sex; age; date and method of diagnosis; histology (ICD-O 3); T, N, M and stage at the time of diagnosis; and date of follow-up or death. End of follow up was 31 December 2015. Multiple imputation (MI) was performed to estimate cases with unknown stage. Actuarial and Kaplan-Meier methods and Cox regression models were used.Results: 2060 cases were identified. 15% were women and 65.2% were 65 years or older. 3.7% had no stage (benign or undetermined behaviour) and 12.5% had unknown stage. After MI, 35.7% were in stage Ta (non-invasive papillary carcinoma), 3.1% in stage Tis (carcinoma in situ), 33.3% in stage I, 11.9 % in Stage II, 4.7% in stage III, and 11.1% in stage IV. Survival was 73% at 5 years. Survival by stage: 98% at stage Ta, 88% at stage Tis, 84% at stage I, 44% at stage II, 33% at stage III, and 7% at stage IV. The Cox model showed that age, histology, and stage were associated with survival.Conclusion: Bladder and urinary tract cancers survival vary greatly with stage. The percentage of non-invasive cancers was high. Stage, age and histology are associated to survival, but sex has no association.

Sign in / Sign up

Export Citation Format

Share Document